New Cleveland Clinic research published in Cancer Cell shows that people with glioblastoma have more active platelets, which are cells involved in blood clotting. Platelets also communicate with other cells and can influence immune activity. The overactive platelets in people with glioblastoma slow the activity of cancer-fighting T cells, which can contribute to tumor growth and cancer progression. Researchers from the lab of Justin Lathia, PhD, continue to investigate the unknowns around sex d

Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities with human brain Findings suggest that TUSC2 may play a foundational role in brain health Oct. 21, 2026 -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-pro

Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1 Median time-to-next-treatment(TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1 Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, follicu

First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study results, demonstrating roginolisib’s favorable tolerability profile and encouraging clinical findings in patients with cancer, including metastatic uveal melanoma (mUM) Publication of the peer-reviewed papers comes as iOnctura awaits readouts from its two fully-enrolled, randomize

Anthropic has released some early findings that suggest its AI may be able to help researchers sift through the vast and expanding universe of genomic data to uncover previously hidden biology. "Today we announced the Claude-led discovery of a molecular machine that we suspect could represent a new gene editing mechanism," CEO Dario Amodei posted on social media Wednesday. "Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is w

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Developmen Sept. 13, 2026 -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conju

Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. Sept. 7, 2026 -- On September 7, 2026, Shanghai, Cell Stem Cell published online clinical research from CorrectSequence Therapeutics (Correctseq) in collaboration with multiple institutions in a paper titled "Clinical base editing for β-hemoglobinopathies across different genetic backgrounds", demonstrating tha

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile– –New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life Sept. 01, 2026 -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biot

Aug. 18, 2026 -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, announced today that new data from a multi-institutional feasibility clinical trial across 15 institutions nationwide presented by Clark Chen, M.D., Ph.D., professor and director of the Brain Tumor Program at Brown University Health, suggest that a novel radiation therapy device may help improve outcomes for patients newly diagnosed with glioblastoma, one of th

Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2. Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile. TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer. July 22, 2026 -- Teli